Kateřina Machová Poláková

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

Johan Richter, Joëlle Guilhot, Franz Gruber et al. · The Lancet Oncology · 2018 · 611 citations · Full text

Medicine, Oncology, Pharmacology +11

Unraveling the complexity of tyrosine kinase inhibitor–resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain

Simona Soverini, Caterina De Benedittis, Kateřina Machová Poláková et al. · Blood · 2013 · 162 citations · Full text

Medicine, Molecular Biology, Molecular Medicine +14

Expression patterns of microRNAs associated with CML phases and their disease related targets

Kateřina Machová Poláková, Tereza Lopotová, Hana Klamová et al. · Molecular Cancer · 2011 · 142 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +17

Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology

Lenka Hovorková, Markéta Žaliová, Nicola C. Venn et al. · Blood · 2017 · 134 citations · Full text

Life Sciences, Genetics, Pediatrics +7

A certified plasmid reference material for the standardisation of BCR–ABL1 mRNA quantification by real-time quantitative PCR

Helen White, Liesbet Deprez, Philippe Corbisier et al. · Leukemia · 2014 · 81 citations · Full text

Life Sciences, Molecular Biology, Molecular Genetics +13